Global Rotavirus Vaccine Market Is Anticipated To Grow At A Cagr Of 10.1% During 2024 To 2030

By Author: Lucintel LLC
Total Articles: 4213
Comment this article

The future of the global rotavirus vaccine market looks promising with opportunities in the hospital and clinic, academic, and research markets. The global rotavirus vaccine market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 10.1% from 2024 to 2030. The major drivers for this market are augmenting cases and mortality of rotavirus infection and rising awareness about the benefits of rotavirus vaccines among healthcare professionals and parents/caregivers.
Some of the key questions answered in this exclusive report are:
Q.1. What are some of the most promising, high-growth opportunities for the rotavirus vaccine market by type (rotarix, rotateq, rotavin-m1, lanzhou lamb, and others), end use (hospitals and clinics, academic and research, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are ...
... the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Market Segmentation:
In this market, rotarix, rotateq, rotavac, rotavin-m1, and lanzhou lamb are the major segments of rotavirus vaccine market by type. Lucintel forecasts that rotarix is expected to witness highest growth over the forecast period. Within this market, hospitals and clinics is expected to witness highest growth over the forecast period as they have the necessary infrastructure and expertise to safely and effectively administer rotavirus vaccines.
APAC is expected to witness highest growth over the forecast period due to growing demand for early detection and treatment of rotavirus infections, rising investment in healthcare infrastructural development, and continuous population growth in the region.
Biovirx, Serum Institute of India, Merck & Co, Bharat Biotech, Biological E, Bio Farma, Novartis, Glaxosmithkline, Sanofi, and Lanzhou Institute of Biologicals Products are the major suppliers in the rotavirus vaccine market.
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market

2. Medical Battery Market

3. Stent Market

4. Wheelchair Market

5. 3D Printing Medical Device Market

6. Medical Device Market

7. Diagnostic Imaging Market

8. Medical Lifting Sling Market

9. Liquid Biopsy Market

10. Stretcher Market